ObvioHealth Appoints Richard Watkins as Chief Revenue Officer
ObvioHealth, a global leader in digital clinical trial solutions, has made a strategic leadership move by appointing Richard Watkins as its Chief Revenue Officer (CRO). This appointment comes during a crucial phase for the company as it transitions into offering comprehensive enterprise solutions. Richard brings over 20 years of experience in sales leadership, particularly within SaaS-based technology solutions focusing on Data, Analytics, and Artificial Intelligence platforms.
A Transformational Moment for ObvioHealth
The arrival of Richard is particularly timely, as ObvioHealth is in the midst of an important transition. Since its inception in 2017, the company has driven significant changes in the clinical trial landscape by pioneering digital transformations. In 2024, ObvioHealth evolved from a Virtual Research Organization (VRO) to an enterprise software provider, marked by the launch of ObvioGo 2.0, which represents a new era of growth for the organization.
Empowering Clinical Trials with Advanced Solutions
ObvioGo 2.0 has positioned the company to deliver state-of-the-art, scalable digital solutions to research partners. The platform offers seamless end-to-end (E2E) capabilities, enabling the rapid design and implementation of clinical trials while supporting efficient patient and site management in a user-friendly, AI-powered environment.
Leadership Experience Enhancing Growth
With Richard's successful track record, especially from his previous role as Senior Vice President of Sales at GlobalData, ObvioHealth anticipates accelerated growth. In this role, he led the Healthcare Division in the US, providing data-driven insights and innovative sales strategies that catered to the pharmaceutical and healthcare markets.
“We are excited to welcome Richard at such a transformative time,” said Ivan Jarry, CEO of ObvioHealth. “His extensive experience in the Life Sciences and Healthcare sectors will be vital as we advance our enterprise solutions. Richard’s leadership is expected to facilitate the widespread adoption of ObvioGo across various sectors including CROs, Pharmaceuticals, Biotech, and Digital Therapeutics, allowing stakeholders to effectively manage clinical trial portfolios at an enterprise level.”
Pioneering Future Innovations in Clinical Trials
The launch of ObvioGo 2.0 marks a significant leap forward in the capabilities offered to pharmaceutical companies and research organizations, equipping them with powerful tools to streamline and scale their clinical trials. This AI-native platform enhances flexibility, accommodating a broad spectrum of studies, from small trials to large-scale, complex projects.
Collaboration and Commitment to Excellence
Through collaboration with leading sponsors, Contract Research Organizations (CROs) such as Novotech, and technology partners including Oracle Life Sciences, ObvioHealth is positioning itself at the forefront of clinical trial solutions. These alliances, paired with cutting-edge technology, ensure that the services and solutions provided are both innovative and scalable to meet clients' growing needs.
ObvioHealth is dedicated to ensuring the effective adoption of its ObvioGo platform. To achieve this, the company utilizes an enterprise enablement process designed to support clients throughout every stage of study design and execution. This structured approach includes thorough training, collaboration on study design, and ongoing support, allowing clients to fully leverage the platform for their clinical trials.
About ObvioHealth
ObvioHealth is at the forefront of digital health, trailblazing new paths in digital clinical trials. Through its proprietary ObvioGo platform, the company is delivering technology-enabled solutions that produce robust evidence and enhance patient-centric outcomes for pharmaceutical, biotech, and research partners. By simplifying the clinical trial process, ObvioHealth is making clinical research more efficient and accessible.
Frequently Asked Questions
What is the significance of Richard Watkins' appointment at ObvioHealth?
Richard Watkins' experience in sales leadership will drive revenue growth and support the company's transition to enterprise solutions, particularly enhancing the adoption of ObvioGo.
What is ObvioGo 2.0?
ObvioGo 2.0 is the latest platform from ObvioHealth that offers powerful tools and capabilities for the design and execution of clinical trials, aimed at simplifying the process for researchers.
How does ObvioHealth support the adoption of its solutions?
The company provides a comprehensive enablement process that includes training and ongoing support, ensuring that clients can effectively utilize ObvioGo in their trials.
What kind of partnerships does ObvioHealth engage in?
ObvioHealth collaborates with various sponsors, CROs, and technology partners, including Novotech and Oracle Life Sciences, to enhance its offerings and deliver effective clinical trial solutions.
How does ObvioHealth simplify clinical trials?
By leveraging the ObvioGo platform, ObvioHealth streamlines processes, improving efficiency and accessibility for both participants and researchers in clinical trials.